Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

63%

5 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 3

4(66.7%)

Phase 2

1(16.7%)

Phase 4

1(16.7%)

6Total

Phase 3(4)

Phase 2(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07477119Phase 4Not Yet Recruiting

Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment

Role: collaborator

NCT04260477Phase 3Recruiting

Novel Triple-dose Tuberculosis Retreatment Regimen

Role: collaborator

NCT03662022Phase 3Completed

Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar

Role: collaborator

NCT05406479Phase 2Completed

Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2)

Role: collaborator

NCT03303963Completed

DIAgnostics for Multidrug Resistant Tuberculosis in Africa

Role: collaborator

NCT03526718Completed

Improved Understanding of Ongoing Transmission of Leprosy in the Hyperendemic Comoros (ComLep)

Role: collaborator

NCT02153528Phase 3Completed

Optimization of the TB Treatment Regimen Cascade

Role: lead

NCT03862248Phase 3Withdrawn

Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More

Role: collaborator

All 8 trials loaded